Analytical Data
-
Gene name
CAPN14
- Application
-
Alternative Names
Calcium-activated neutral proteinase 14
-
Species
Human
-
Source
Baculovirus
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A8MX76
-
Expression Region
43-684aa
-
Molecular Weight
78.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CAPN14, a member of the calpain family of cysteine proteases, has garnered attention in recent years due to its specific and critical role in the physiology of the auditory system. Unlike other calpains, CAPN14 is predominantly expressed in the cochlea, where it is implicated in the regulation of cellular processes that are essential for maintaining hearing function. Research has shown that mutations in the CAPN14 gene are associated with nonsyndromic hearing loss, highlighting its importance in auditory health. The protein is thought to participate in various signaling pathways that govern cellular responses to mechanical stress and apoptosis in hair cells of the inner ear. Given its unique expression pattern and functional significance, CAPN14 represents a promising target for investigating novel therapeutic strategies to address hearing disorders. Recombinant CAPN14 protein has become an essential tool for studying its biochemical properties and elucidating its role in cochlear function and damage. Studies involving the reconstitution of CAPN14 in vitro will facilitate a deeper understanding of its enzymatic activity, substrate specificity, and interaction with other cellular components. This knowledge could pave the way for advances in gene therapy and regenerative medicine approaches aimed at preventing or treating hearing loss, thus enhancing the quality of life for affected individuals. Overall, the exploration of CAPN14 as a therapeutic target holds significant potential in the field of auditory research.
